TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8096670
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers alone
Study: 19647928
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (rtPA)
Study: 12740311
Drug: Alcohol-displacement (A)
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-displacement (A) diet (1.5 g/kg alcohol displacing CHO energy from control)
Study: 31736269
Drug: Dexamethasone implant
Normalized name: dexamethasone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone implant (Ozurdex)
Study: 8976353
Drug: Vein Patch
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein Patch Closure (SVP)
Study: 26669916
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) monotherapy
Study: 17786886
Drug: Other mood
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other mood stabilizers and antidepressants
Study: 22241281
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg haloperidol
Study: 25226311
Drug: Citrulline malate
Normalized name: CITRULLINE MALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline malate (8 g)
Study: 30385039
Drug: Low-dose prednisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisone plus enteric-coated mycophenolate sodium
Study: 17097995
Drug: Five bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five bolus doses of daclizumab
Study: 8548226
Drug: Iron saccharate
Normalized name: Iron saccharate
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron saccharate 200 mg/day intravenously for 12 consecutive days
Study: 24569099
Drug: Twice-daily perphenazine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily perphenazine dosing
Study: 18379357
Drug: Vandetanib 200
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib 200 mg
Study: 19332730
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg
Study: 24385118
Drug: Topical cosmetic
Normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cosmetic formulation
Study: 7758556
Drug: Baclofen 25
Normalized name: baclofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 25 mg before sleep
Study: 23702435
Drug: Sublingual ketorolac
Normalized name: ketorolac Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual ketorolac (0.5 mg/kg)
Study: 9856522
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination
Study: 14685040
Drug: Hyposensitization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyposensitization therapy (duration not specified).
Study: 3496186
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (enteric-coated and plain)
Study: 3675695
Drug: Amoxicillin 1000
Normalized name: amoxicillin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1000 mg p.o.t.i.d.
Study: 17668348
Drug: Cocaethylene infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cocaethylene infusion at 0 ng/mL (placebo)
Study: 8646474
Drug: Corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injections
Study: 3315270
Drug: 2000 hr
Normalized name: sulfalene 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 hr dosing of Armophylline (600-900 mg/24 hr)
Study: 7760967
Drug: T3 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 therapy (75-100 micrograms T3 daily)
Study: 12368690
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 1 g/kg/dose x2
Study: 21542914
Drug: Hip school
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip school + Manual therapy (group B)
Study: 8560161
Drug: Intranasal immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal immunotherapy with Dermatophagoides extract
Study: 15030340
Drug: Bexarotene gel
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bexarotene gel monotherapy
Study: 31860632
Drug: Oral flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral flurbiprofen
Study: 26203169
Drug: Deworming drugs
Normalized name: oxfendazole
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deworming drugs
Study: 8045623
Drug: Traditional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapies
Study: 30523659
Drug: Hybrid intervention
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid intervention combining exergaming and physical therapy
Study: 9631990
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg
Study: 9631990
Drug: Fluconazole 450
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 450 mg
Study: 10830739
Drug: Non-randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-randomized treatment group
Study: 10830739
Drug: Randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatment group
Study: 6274503
Drug: Hyperthermia combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia combined with high-dose-rate external beam radiotherapy
Study: 7789550
Drug: Nal-Glu 100
Normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nal-Glu 100 micrograms/kg per day + T enanthate 50 mg IM weekly
Study: 30321655
Drug: Placebo (twice-daily)
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo (twice-daily)
Study: 16418021
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of ropivacaine (150 mg)
Study: 25818103
Drug: Regular oral
Normalized name: infant formula,regular ORAL PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular oral instructions (Control group).
Study: 19151299
Drug: Gabapentin 1200-1600
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200-1600 mg
Study: 10665617
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration (sublingual)
Study: 9332680
Drug: Zorubicin 325
Normalized name: zorubicin
DrugBank: Zorubicin (DB11618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zorubicin 325 mg/m2, day 1 (Group A)
Study: 9332680
Drug: Zorubicin 250
Normalized name: zorubicin
DrugBank: Zorubicin (DB11618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zorubicin 250 mg/m2, day 1 and cisplatin 30 mg/m2, days 2-5 (Group B)
Study: 9511041
Drug: Doxycycline therapy
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline therapy for 4 months
Study: 9141518
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg
Study: 31221280
Drug: Normal sodium
Normalized name: sulfacetamide sodium Medicated Pad [Rosula NS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal sodium diet (NS: 7 g/day of dietary sodium chloride)
Study: 15619680
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once weekly
Study: 8751522
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin
Study: 24586717
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of MR vaccine administered at 8 months and second dose of MMR vaccine administered at 18-24 months
Study: 30196900
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g sucrose
Study: 27382812
Drug: Intrathecal Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal Fentanyl (25 µg) added to bupivacaine (10mg)
Study: 28937845
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate MDI 320 mcg (80 mcg/inhalation, 4 inhalations)
Study: 30466512
Drug: NT-proBNP-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP-guided therapy
Study: 31976786
Drug: Cisplatin 25
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 intravenously on days 3 and 10; plus veliparib 80 mg orally twice per day on days 1 to 12, cycled every 3 weeks (Arm A)
Study: 31976786
Drug: Cisplatin 25
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 intravenously on days 3 and 10 (Arm B)
Study: 8554083
Drug: Low-dose levodopa
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose levodopa and carbidopa
Study: 20978247
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg/kg
Study: 23549151
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) for the treatment of food allergy
Study: 26945662
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Finasteride daily for 2 weeks before TURP
Study: 11336101
Drug: Fluvastatin extended-release
Normalized name: Fluvastatin Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin extended-release 320 mg
Study: 9601592
Drug: Bupivacaine gel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine gel (2.5 mg/ml)
Study: 10807025
Drug: Treatment intensity
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment intensity in the last month of life for all age groups
Study: 17563309
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin
Study: 25643864
Drug: Mind Reading
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mind Reading and in vivo rehearsal treatment
Study: 12660911
Drug: Randomized placebo-controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized placebo-controlled trial of an injectable medicine given throughout pregnancy
Study: 9135193
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg intrathecal morphine
Study: 14747881
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg o.d.
Study: 19446324
Drug: Early exercise
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early exercise and mobilisation (physical and occupational therapy) during periods of daily interruption of sedation
Study: 1647193
Drug: Granisetron and
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron and Lorazepam (in combination)
Study: 25008878
Drug: Intratracheal injection
Normalized name: Intratracheal Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal injection of porcine pulmonary surfactant (PS)
Study: 20473044
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg/d
Study: 19149900
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated split virus influenza vaccine (TIV)
Study: 26422093
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg (for children > 20 kg)
Study: 2265237
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg PPA HCl CR caplet once daily for 4 days
Study: 31244327
Drug: Integrated programme
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated programme of physical and electrical therapy
Study: 17130031
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (n = 38) received 1 g paracetamol and 100 mg diclofenac
Study: 8565027
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 10 mg once daily in the morning
Study: 1385913
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (group C)
Study: 3028456
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate 10 mg
Study: 25599738
Drug: Routine anti-rejection
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine anti-rejection medication only (n = 32)
Study: 11085197
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) administration
Study: 20558755
Drug: L-NAME +
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME + ketorolac infusion
Study: 29249276
Drug: Adjunctive rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive rifampicin
Study: 18211754
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with 'Dermatophagoides Farinae Drops' (n = 139)
Study: 24200231
Drug: 3% diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diquafosol ophthalmic solution
Study: 6110436
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg four times daily for 1 week (alone)
Study: 22520733
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy combined with bevacizumab and erlotinib
Study: 28074421
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed combination antiretroviral therapy (DOT-cART)
Study: 30333315
Drug: Ketoprofen 75
Normalized name: ketoprofen 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 75 mg by mouth 3 times daily for 4 months
Study: 29193743
Drug: Specialized Early
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized Early Intervention (SEI) treatment (OPUS treatment)
Study: 12547469
Drug: Selegiline hydrochloride
Normalized name: Selegiline Hydrochloride
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selegiline hydrochloride (5 mg p.o. twice daily)
Study: 7488417
Drug: Granisetron alone
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron alone (group G)
Study: 18685511
Drug: Synbiotic formulation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic formulation A (3 probiotic strains and FOS)
Study: 1304727
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg of oral clonidine
Study: 25140469
Drug: Right internal
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right internal thoracic artery (RITA) pedicled to LAD and left internal thoracic artery (LITA) pedicled to circumflex in Group-2 (G-2)
Study: 26582579
Drug: Natural mineral
Normalized name: ZINC OXIDE 8.25 g in 44 mL TOPICAL LOTION [Natural Mineral Formula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural mineral water (500 mL)
Study: 1743242
Drug: Transdermal delivery
Normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal delivery system (TDS) with phasic release of glyceryl trinitrate (GTN)
Study: 28982672
Drug: Extended-release torsemide
Normalized name: Torsemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release torsemide
Study: 11888512
Drug: HMG CoA
Normalized name: HMG CoA reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG CoA RI therapy (pravastatin 40 mg QD or simvastatin 20 mg QD)
Study: 16926581
Drug: Interdisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary treatment
Study: 15592276
Drug: Goserelin injection
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin injection (3.6 mg/month)
Study: 14629242
Drug: Almotriptan 12.5
Normalized name: almotriptan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 12.5 mg
Study: 1872271
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg and 10 mg
Study: 9291168
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 0.15-0.2 g/kg body weight, administered monthly for 2 years
Study: 30682359
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen 1000 mg
Study: 25912040
Drug: Experimental soy-based
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental soy-based formula 1 (EF1) containing scFOS (2.5 g/L) and mixed carotenoids
Study: 28522078
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance therapy (OAT)
Study: 15633323
Drug: Anesthetic gel
Normalized name: Topicaine 4% Topical Anesthetic Gel
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic gel
Study: 3651264
Drug: Split-course radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split-course radiation therapy with a 5-week rest interval
Study: 9177549
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg
Study: 3117400
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) group, intravesical instillation with 30 mg MMC dissolved in 100 ml physiological saline; administered six times within 2 weeks, then every 4 weeks for 2 years.
Study: 11137327
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy with E2 (50 microg/day) and NETA (350 microg/day)
Study: 30194765
Drug: Therapeutic levels
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic levels of hypoglossal nerve stimulation therapy (HGNS)
Study: 22093109
Drug: Synbiotics treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics treatment
Study: 15963058
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose testosterone (Te) supplementation
Study: 9480468
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic regimen (gentamicin, clindamycin)
Study: 9480468
Drug: Curative antibiotic
Normalized name: CUR-1916
DrugBank: CUR-1916 (DB17838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative antibiotic treatment (intraoperatively)
Study: 29627296
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ERN)
Study: 7019300
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment consisting of preliminary chemotherapy (AVM or CMF), radiotherapy, and follow-up adjuvant chemotherapy.
Study: 16123103
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P + 10 mm L-NAME
Study: 28120631
Drug: Minimal intervention
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal intervention (monthly written information bulletins and monthly phone calls)
Study: 23884046
Drug: 4-week educational
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week educational intervention involving weekly 60-minute sessions (Group A)
Study: 15872036
Drug: Pexelizumab 24
Normalized name: Pexelizumab
DrugBank: Pexelizumab (DB04949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab 24 h infusion